A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 Study
Launched by ABBOTT · Dec 16, 2008
Trial Information
Current as of May 27, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • The subject was randomized into Study M06-876 and completed the study.
- • The subject must remain on the same dose of AChEI that was used during the M06-876 study.
- • The subject is in general good health, as judged by the investigator
- Exclusion Criteria:
- • The subject is currently, or plans to participate in another experimental study during the course of this trial.
- • The subject anticipates a move outside the geographic area of the investigative site or is planning extended travel inconsistent with the recommended visit intervals.
About Abbott
Abbott is a global healthcare company dedicated to improving lives through innovative medical technologies, diagnostics, nutrition, and branded generic pharmaceuticals. With a commitment to advancing health and wellness, Abbott conducts clinical trials to evaluate the safety and efficacy of its diverse portfolio of products, which span multiple therapeutic areas, including cardiovascular, diabetes care, and neurology. The company employs rigorous research methodologies and collaborates with healthcare professionals and institutions worldwide to ensure the highest standards of clinical integrity and patient safety. Abbott's mission is to deliver impactful solutions that enhance patient outcomes and contribute to the advancement of global healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Phoenix, Arizona, United States
Sun City, Arizona, United States
Fresno, California, United States
San Diego, California, United States
Santa Monica, California, United States
Hamden, Connecticut, United States
Brooksville, Florida, United States
Deerfield Beach, Florida, United States
Delray Beach, Florida, United States
Miami, Florida, United States
Palm Beach Gardens, Florida, United States
Sunrise, Florida, United States
Tampa, Florida, United States
West Palm Beach, Florida, United States
Indianapolis, Indiana, United States
Eatontown, New Jersey, United States
Ridgewood, New Jersey, United States
New York, New York, United States
Winston Salem, North Carolina, United States
Centerville, Ohio, United States
Wichita Falls, Texas, United States
Bennington, Vermont, United States
Patients applied
Trial Officials
Robert Lenz
Study Director
Abbott
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials